Skip to content
2000
Volume 9, Issue 7
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy- Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955709788452595
2009-06-01
2025-09-26
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955709788452595
Loading

  • Article Type:
    Research Article
Keyword(s): CC-4047; CC-5013; CIPN; IMiDs; lenalidomide; pomalidomide; safety; side effects; thalidomide
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test